Real-world data on the treatment of ulcerative colitis with Daifu Decoction: a retrospective study

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2024000560

Enrollment

Unknown

Registered

2024-10-15

Start date

2024-11-01

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Daifu Decoction Group:Daifu Decoction

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Regular application of Daifu decoction treatment; 2) Complete colonoscopy at 8 weeks of initial visit and treatment; 3) No 5-amino acid salicylic acid drugs (including methalazine and sulfasalazine) hormones/ immunosuppressants or biologics were used during treatment.

Exclusion criteria

Exclusion criteria: Cases with incomplete data were excluded.

Design outcomes

Primary

Measure	Time frame
recurrence rate;	—

Secondary

Measure	Time frame
TCM syndrome score;IBDQ score;total effective rate;improved Mayo score;	—

Countries

China

Contacts

Public ContactGong Yang

General Hospital of Northern Theater Command

goongyang126@126.com13309888136

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026